City of Hope scientists have developed and tested the first chimeric antigen receptor therapy using chlorotoxin, a component of scorpion venom, to direct T cells to target brain tumor cells, according to a preclinical study published March 4 in Science Translational Medicine. The institution has also opened the first in-human clinical trial to use the therapy.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
